Apparatus for enhancing wound healing

Abstract
A wound therapy apparatus for enhancing healing of a wound includes a wound dressing configured for placement over the wound to define a reservoir over the wound in which a wound contact fluid may be maintained by forming a substantially fluid-tight seal around the wound. An elastic bladder member defined by or within the wound dressing is expandable to exert a pressure on the wound contact fluid within the reservoir. A fluid system is in fluid communication with the reservoir for selectively delivering the wound contact fluid to the reservoir, and a pressure system is in fluid communication with the bladder member for delivering a compressed liquid or gas to the bladder member to effect expansion in the bladder member.
Description
BACKGROUND

1. Technical Field


The present disclosure relates generally to an apparatus for generating and maintaining an environment around a wound to enhance healing of the wound. In particular, the disclosure relates to an apparatus including a fluid system for providing a fluid to the wound and dressing for providing a pressure to the fluid.


2. Background of Related Art


The body's natural wound healing process is a complex series of events beginning at the moment of injury. Initially the body reacts by delivering proteins and other factors to the wound through the blood stream to minimize the damage. Blood clots to prevent blood loss while cells engulf bacteria and debris to carry it away from the wound site. Next, the body begins to repair itself in a stage of healing often referred to as the “proliferate” phase. This phase is characterized by the deposition granulation tissue in the wound bed. Granulation tissue provides a base structure over which cells may migrate inwardly from the periphery to close the wound. Finally the process ends as collagen gives strength to new tissue over time often forming a scar.


Throughout the healing process, the body has a natural tendency to break down dead tissue and debris, thereby cleaning the wound and allowing new cells to form. This natural process is often referred to as autolytic debridement. One technique for promoting autolytic debridement, and wound healing generally, involves the application of a pressure to a wound. The application of both positive and negative pressures to a wound has proven effective in closing and healing the wound by promoting blood flow to the area, stimulating the formation of granulation tissue and the migration of healthy tissue over the wound by the natural process. Also, reduced pressures may assist in removing fluids exuding from the wound, which may inhibit bacterial growth. These techniques have proven effective for chronic or non-healing wounds, but have also been used for other purposes such as post-operative wound care.


The application of pressure to a wound may be facilitated by an apparatus permitting the environment around the wound to be controlled. Accordingly, an apparatus defining a reservoir around a wound where a pressure may be controlled may prove beneficial.


SUMMARY

The present disclosure describes an apparatus for enhancing healing of a wound. The apparatus includes a wound dressing configured for placement over the wound to define a reservoir over the wound in which a wound contact fluid may be maintained by forming a substantially fluid-tight seal around the wound. An elastic bladder member defined by or within the wound dressing is expandable to exert a pressure on the wound contact fluid within the reservoir. A fluid system is in fluid communication with the reservoir for selectively delivering the wound contact fluid to the reservoir, and a pressure system is in fluid communication with the bladder member for delivering a compressed liquid or gas to the bladder member to effect expansion in the bladder member.


The elastic bladder member may be coupled to a substantially inelastic backing layer and the backing layer may be coupled to a body attachment layer for contacting the skin around the wound. Expansion of the bladder member may then effect a tension in backing layer to the draw the skin around the wound inwardly. The elastic bladder member may be coupled to the substantially inelastic backing layer by an inner adhesive ring nested within an outer adhesive ring. The inner adhesive ring may encircle a fluid communication portal providing fluid communication between the reservoir and the fluid system.


Alternatively, the elastic bladder member may be coupled to an elastic backing layer and the backing layer may be coupled to a reinforcement layer providing bilateral stiffness to the dressing. The reinforcement layer may comprise a mesh formed from polyethylene terephthalate fibers, and the backing layer may be constructed from urethane.


The wound contact fluid may comprise a medicament to promote wound healing such as a debridement agent, an antimicrobial agent, polyhexamethylene biguanide, an antibiotic, a growth factor or an analgesic. The fluid system may comprise a syringe repeatably detachable from the apparatus.


According to another aspect of the disclosure, a wound dressing for enhancing healing of a wound includes a substantially elastic backing layer configured for placement over a wound to define a reservoir over the wound in which a wound contact fluid may be maintained by forming a substantially fluid-tight seal around the wound. A reinforcement layer is adhered to the backing layer for providing a bilateral stiffness to the wound dressing and extends to a peripheral region of the backing layer. An elastic bladder member defined by or within the wound dressing is expandable to exert a pressure on the wound contact fluid within the reservoir. The elastic bladder member includes a fluid communication port therethrough to permit introduction of the wound contact fluid to the wound. The backing layer may be coupled to a portal member, which includes a central bore to permit introduction of the wound contact fluid and a distinct interior distribution ring to permit introduction to a compressible liquid or gas to a pressure application zone of the bladder member.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.



FIG. 1 is an exploded perspective view of a wound therapy apparatus in accordance with the present disclosure;



FIG. 2 is an exploded cross sectional view of the wound dressing of FIG. 1;



FIG. 3 is a cross sectional view of the wound dressing of FIG. 1 applied on a wound; and



FIG. 4 is an exploded cross sectional view of an alternate embodiment of a wound dressing in accordance with the present disclosure.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts throughout the several views.


Referring initially to FIG. 1, a wound therapy apparatus according to the present disclosure is depicted generally as 10 for use on a wound “w” surrounded by healthy skin “s.” The apparatus 10 includes a wound dressing 12 for placement over the wound “w” to define a reservoir 14 (FIG. 3) over the wound in which a fluid may be maintained. The apparatus 10 also includes a fluid system 16 in fluid communication with the reservoir 14, and a pressure system 18 in fluid communication with the wound dressing 12. A portal member 20 provides a mechanism for connecting various fluid conduits 22, 24 to the wound dressing 12 to facilitate fluid communication with the fluid system 16 and pressure system 18.


The wound dressing 12 is a composite dressing formed from the lamination or juxtaposition of several distinct layers. First, a release paper 26 is positioned at a distal or wound facing side of the dressing 12. The release paper 26 is configured to protect the dressing 12 prior to the application of the dressing 12 to the wound “w,” and may be removed from the dressing 12 and discarded just before the dressing 12 is applied. Release paper 26 need not be constructed of paper, but may be formed from any suitable material including polyurethane, metallic foils, polyolefins and polyesters.


Positioned on a proximal side of the release paper 26 is a body attachment layer 28. The body attachment layer 28 includes a central opening 30 extending laterally beyond the perimeter of the wound “w” such that a body attachment adhesive 32 may contact the healthy skin “s” to form a seal around the wound “w.” To form an appropriate seal, body attachment adhesive 32 may be constructed from a medical-grade, pressure-sensitive adhesive adapted to provide a fluid-tight and bacteria-tight seal around a peripheral region of the dressing 12. In this manner, wound contact fluids 34 (see FIG. 3) will not tend to escape through the edges of the dressing 12, and external contaminants may not enter the wound area. To provide such a barrier, the body attachment adhesive 32 may, for example, be on the order of 1.0 to 10 mils thick depending on the adhesive used. In general, a high peal-strength adhesive may be used to resist inadvertent lift-off, roll or “flagging,” i.e., a failure of the dressing to adhere to itself or the skin “s,” at the edges of the dressing. The adhesive defining body attachment adhesive layer 32 may include, but is not limited to, medical grade acrylics, rubber base or silicone adhesives. Preferably, those adhesives included with the dressing sold under the trademark POLYSKIN®II offered by Tyco Healthcare Group LP (d/b/a Covidien) may be used.


Positioned within the central opening 30 of the body attachment layer 28 is a bladder member 36. Alternatively, bladder member 36 can be positioned upon body attachment layer 28 to cover or traverse central opening 30. Bladder member 36 is constructed of an elastically deformable elastomer or similar material, and includes a fluid communication portal 38 extending through a central region. An upper surface of the bladder member 36 includes nested rings 40, 42 of a permanent adhesive thereon. An inner ring 40 encircles the fluid communication portal 38 in the central region while outer ring 42 extends to a periphery of the bladder member 36. A pressure application zone 44 is defined between the two nested rings 40, 42.


Disposed over the bladder member 36 is a backing layer 48. Backing layer 48 is substantially inelastic relative to the bladder member 36 and may be constructed from a flexible polymeric membrane. For example, backing layer 48 may comprise a polyurethane film having a thickness from about 0.8 mils to about 1.0 mil. A membrane that provides a sufficient moisture vapor transmission rate (MVTR) is a transparent membrane sold under the trade name POLYSKIN®II offered by Tyco Healthcare Group LP (d/b/a Covidien). Other materials which may be suitable for use in a backing layer include the thin films marketed under the names TEGADERM™ by 3M of St. Paul, Minn. and OPSITE™ by Smith and Nephew PLC of London, UK.


The backing layer 48 adheres to the bladder member 36 due to contact with the nested adhesive rings 40, 42. A fluid hole 50 extends through backing layer 48 in general alignment with the fluid communication portal 38 of the bladder member 36. A pair of pressure supply holes 52 flank the fluid hole 50 such that the pressure supply holes 52 communicate with the pressure application zone 44 of the bladder member 36. The inner adhesive ring 40 extends between the fluid hole 50 and the pressure supply holes 52 such that the fluid hole 50 and the pressure supply holes 52 are fluidly distinct. The backing layer 48 also adheres to the body attachment layer 28 such that the dressing 12 may form a reservoir 14 over the wound “w.”


Portal member 20 adheres to an upper surface of the backing layer 48 in a substantially fluid tight manner. A suitable adhesive 56 is disposed about a perimeter of on an underside of the portal member 20 to facilitate this connection. Alternatively, an adhesive may be disposed on the upper surface of the backing layer 48, or other fluid tight arrangements may be appropriate. Portal member 20 includes a hollow central bore 58, which provides fluid communication between the fluid hole 50 and the fluid conduit 22 leading to the fluid system 16. Portal member 20 also includes a distinct interior air distribution ring 60, which provides fluid communication between the pressure supply holes 52 and the fluid conduit 24 leading to the pressure system 18. Portal member 20 may include check valves (not shown) within the central bore 58 and the distribution ring 60 for retaining fluids within the reservoir 14 and pressure application zone 44.


The fluid system 16 is in fluid communication with the reservoir 14 as described above. Fluid system 16 serves to evacuate the reservoir 14 and also to supply the reservoir 14 with wound contact fluid 34. The wound contact fluid 34 is generally a low viscosity fluid such that it may conform to the particular geometry of the wound “w,” and may adapt as the geometry of the wound “w” changes during healing. The wound contact fluid 34 may include a beneficial agent such as a medicament to promote wound healing. Medicaments include, for example, antimicrobial agents, polyhexamethylene biguanide, growth factors, antibiotics, analgesics, and the like. Suitable medicaments also include debridement agents such as chemical compounds or enzymes that intimately surround and infiltrate necrotic tissue.


Fluid system 16 comprises a syringe 64 to deliver the wound contact fluid 34. Syringe 64 may be repeatably removable and connectable to the apparatus 10 through a standard luer connection, for example. Syringe 64 may therefore be connected to the apparatus 10 in an empty state to evacuate the reservoir 14, and may then be disconnected so that it may be filled with wound contact fluid 34. Once filled with wound contact fluid 34, syringe 64 may be reattached to the apparatus as shown to deliver the wound contact fluid 34 to the reservoir 14. Alternatively, the fluid system 16 may comprise multiple syringes, a reversible electric pump, or a similar mechanism to manage the contents of the reservoir 14. A collection canister 64 is selectively coupled to fluid conduit 22 to receive any wound exudates or debris during evacuation of the reservoir 14. Collection canister 64 is removable such that wound contact fluid 34 need not flow into or through the canister 64 as the wound contact fluid 34 is delivered to the reservoir 14.


The pressure system 18 is in fluid communication with the pressure application zone 44 of the bladder member 36. A pressure source 66 is coupled to the pressure application zone 44 through fluid conduit 24, a valve 68, and portal member 20 such that the pressure source 66 may selectively supply a pressurized liquid or gas, air for example, to the pressure application zone 44. Pressure source 26 may be configured to provide the pressurized liquid or gas in a continuous or intermittent fashion.


In use, wound therapy apparatus 10 may be used to apply a pressure to the wound “w” as depicted in FIG. 3. The wound dressing 12 is applied to the skin “s” around the wound “w” defining reservoir 14. Ambient air captured beneath the dressing 12 is evacuated and wound contact fluid 34 is delivered to the reservoir by fluid system 16. Pressure system 18 delivers the pressurized liquid or gas to the pressure application zone 44 of the bladder member 36 such that the bladder member 36 applies a pressure to the wound contact fluid 34 as indicated by arrows “A.” The wound contact fluid 34 conforms to geometry of the wound “w” and delivers an effective pressure to wound “w” to stimulate healing of the wound as indicated by arrows “B.” An effective pressure may, for example, induce cellular surface strain within the wound in the range of from about 5 to about 20 percent.


As used in this manner, dressing 12 may also serve to promote closure of the wound “w.” Bladder member 36 may stretch to accommodate the application of pressure to the pressure application zone 44. Since the backing layer 48 is substantially inelastic relative to the bladder member 36, reactionary forces in the backing layer may exert an inwardly directed force on the margins of the wound “w” as indicated by arrows “C.”


Referring now to FIG. 4, an alternate embodiment of a wound dressing in accordance with the present disclosure is depicted generally as 112. Wound dressing 112 includes a body attachment layer 128 for forming a fluid tight seal with the skin “s” surrounding wound “w.” Positioned within a central opening 130 of the body attachment layer 128 or overlapping a portion of body attachment layer 128 is a lower bladder member 136A. Lower bladder member 136A includes a fluid communication portal 138 to permit the introduction of wound contact fluid 34 to the wound “w.” An upper bladder member 136B is coupled to the lower bladder member 136A by nested adhesive rings 140, 142. The upper bladder member 136B includes a fluid communication portal 138 as well as pressure supply holes 146 in communication with a pressure application zone 144. Both upper and lower bladder members 136A and 136B may be elastic and stretch under the application of pressure from pressure system 18. At an upper surface of dressing 112, backing layer 148 may be constructed of a relatively elastic material such as urethane. Backing layer 148 includes a fluid hole 150 and pressure supply holes 152 to provide fluid communication to the reservoir 14 and pressure application zones 144 respectively.


Disposed between upper bladder member 136B and backing layer 148 is a reinforcement layer 162 providing a bilateral stiffness to the dressing 112. Reinforcement layer 162 may overlap body attachment layer 128 at an outer edge of the dressing 112 such that reactionary forces generated in the dressing 112 may be directed to the skin “s” surrounding the wound “w.” Reinforcement layer 162 may be affixed to backing layer 148 with a light coat of an adhesive 170 applied to the appropriate side of the reinforcement layer 162 or the backing layer 148. Reinforcement layer 162 may be also be affixed to upper bladder member 136B with a light coat of an adhesive 170 applied to the appropriate side of the reinforcement layer 162 or the upper bladder member 136B.


The reinforcement layer 162 may comprise a mesh of polyethylene terephtalate (PET) fibers, which offer good liquid resistance making it suitable for use in a moist wound environment. PET fibers may be used to form woven or non-woven reinforcements having large pore sizes. Some PET reinforcement manufacturing methods provide for interlinking the fiber junctions to yield a mesh that is flexible in multiple directions and also does not unravel when cut. PET reinforcements thus manufactured tend to have a high shear stiffness that may be useful in reinforcing backing layer 148 and providing a bilateral stiffness to dressing 112. One exemplary material, which may be suitable for incorporation into reinforcement layer 162, is sold under the trademark Sontara® by DuPont. Alternatively, reinforcement layer 162 may be formed from another reinforcement or mesh structure having suitable shear stiffness. Examples of suitable structures include extruded thermoplastic netting and apertured films. Suitable materials for use in such alternate structures include PET, polyethylene, nylon and polypropylene. Additionally, woven structures may be used for reinforcement layer 162. Acceptable woven materials may include cotton gauze, woven acetate and nylon.


Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims
  • 1. A wound therapy apparatus for enhancing healing of a wound, comprising: a wound dressing configured for placement over a wound to define a reservoir over the wound in which a wound contact fluid may be maintained by forming a substantially fluid-tight seal around the wound;an elastic bladder member defined by or within the wound dressing and coupled to a substantially inelastic backing layer by an inner adhesive ring nested within an outer adhesive ring, the outer adhesive ring being independent of, and spaced from, the inner adhesive ring, the elastic bladder member being expandable to exert a pressure on the wound contact fluid within the reservoir;a fluid system in fluid communication with the reservoir for selectively delivering the wound contact fluid to the reservoir; anda pressure system in fluid communication with a pressure application zone defined between the inner and outer adhesive rings of the bladder member for delivering a compressed liquid or gas to the pressure application zone of the bladder member to effect expansion in the bladder member.
  • 2. The apparatus according to claim 1, wherein the backing layer is coupled to a body attachment layer for contacting the skin around the wound such that expansion of the bladder member may effect a tension in backing layer to the draw the skin around the wound inwardly.
  • 3. The apparatus according to claim 1, wherein the inner adhesive ring encircles a fluid communication portal providing fluid communication between the reservoir and the fluid system.
  • 4. The apparatus according to claim 1, wherein the wound contact fluid comprises a medicament to promote wound healing.
  • 5. The apparatus according to claim 4, wherein the medicament comprises a debridement agent.
  • 6. The apparatus according to claim 4, wherein the medicament comprises at least one of an antimicrobial agent, polyhexamethylene biguanide, an antibiotic, a growth factor and an analgesic.
  • 7. The apparatus according to claim 1, wherein the fluid system comprises a syringe repeatably detachable from the apparatus.
CROSS REFERENCE TO RELATED APPLICATIONS

The present invention claims the benefit of and priority to U.S. provisional patent application Ser. No. 61/076,753 filed on Jun. 30, 2008, disclosure of which may be referred to herein by reference.

US Referenced Citations (207)
Number Name Date Kind
3081771 Lee Mar 1963 A
3367332 Groves Feb 1968 A
3486504 Austin, Jr. Dec 1969 A
3572340 Lloyd et al. Mar 1971 A
3712298 Snowdon et al. Jan 1973 A
3809086 Schachet et al. May 1974 A
3874387 Barbieri Apr 1975 A
4080970 Miller Mar 1978 A
4112947 Nehring Sep 1978 A
4112949 Rosenthal et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4202331 Yale May 1980 A
4224945 Cohen Sep 1980 A
4266545 Moss May 1981 A
4382441 Svedman May 1983 A
4524064 Nambu Jun 1985 A
4710165 McNeil et al. Dec 1987 A
4738257 Meyer et al. Apr 1988 A
4743232 Kruger May 1988 A
4969880 Zamierowski Nov 1990 A
4990137 Graham Feb 1991 A
4997438 Nipper Mar 1991 A
5071409 Rosenberg Dec 1991 A
5100395 Rosenberg Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5152757 Eriksson Oct 1992 A
5160322 Scheremet et al. Nov 1992 A
5176663 Svedman et al. Jan 1993 A
5178157 Fanlo Jan 1993 A
5195977 Pollitt Mar 1993 A
5261893 Zamierowski Nov 1993 A
5263922 Sova et al. Nov 1993 A
D364679 Heaton et al. Nov 1995 S
5484427 Gibbons Jan 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5588958 Cunningham et al. Dec 1996 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5733305 Fleischmann Mar 1998 A
5779657 Daneshvar Jul 1998 A
5840049 Tumey et al. Nov 1998 A
5911222 Lawrence et al. Jun 1999 A
5944703 Dixon et al. Aug 1999 A
6010524 Fleischmann Jan 2000 A
6071267 Zamierowski Jun 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Tumey et al. Nov 2000 S
6142982 Hunt et al. Nov 2000 A
6174306 Fleischmann Jan 2001 B1
6203563 Fernandez Mar 2001 B1
6261276 Reitsma Jul 2001 B1
6325788 McKay Dec 2001 B1
6345623 Heaton et al. Feb 2002 B1
6348423 Griffiths et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6406447 Thrash et al. Jun 2002 B1
6420622 Johnston et al. Jul 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
D469175 Hall et al. Jan 2003 S
D469176 Hall et al. Jan 2003 S
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
D475134 Randolph May 2003 S
6557704 Randolph May 2003 B1
D478659 Hall et al. Aug 2003 S
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
D488558 Hall Apr 2004 S
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6855860 Ruszczak et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6887228 McKay May 2005 B2
6887263 Bleam et al. May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960181 Stevens Nov 2005 B2
6979324 Bybordi et al. Dec 2005 B2
6994702 Johnson Feb 2006 B1
7022113 Lockwood et al. Apr 2006 B2
7037254 O'Connor et al. May 2006 B2
7052167 Vanderschuit May 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128719 Rosenberg Oct 2006 B2
7128735 Weston Oct 2006 B2
7144390 Hannigan et al. Dec 2006 B1
7169151 Lytinas Jan 2007 B1
7182758 McCraw Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7273054 Heaton et al. Sep 2007 B2
7276051 Henley et al. Oct 2007 B1
7279612 Heaton et al. Oct 2007 B1
7316672 Hunt et al. Jan 2008 B1
D565177 Locke et al. Mar 2008 S
7338482 Lockwood et al. Mar 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7396345 Knighton et al. Jul 2008 B2
7410495 Zamierowski Aug 2008 B2
7413570 Zamierowski Aug 2008 B2
7413571 Zamierowski Aug 2008 B2
7422576 Boynton et al. Sep 2008 B2
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020016577 Ohmstede Feb 2002 A1
20020143286 Tumey Oct 2002 A1
20020151836 Burden Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030078532 Ruszczak et al. Apr 2003 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030208149 Coffey Nov 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer Apr 2004 A1
20040073151 Weston Apr 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040113309 Thompson et al. Jun 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040167482 Watson Aug 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20040249353 Risk, Jr. et al. Dec 2004 A1
20040260230 Randolph Dec 2004 A1
20050004534 Lockwood et al. Jan 2005 A1
20050010153 Lockwood et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050070835 Joshi Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050090787 Risk, Jr. et al. Apr 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050147562 Hunter et al. Jul 2005 A1
20050177190 Zamierowski Aug 2005 A1
20050182445 Zamierowski Aug 2005 A1
20050222527 Miller et al. Oct 2005 A1
20050222544 Weston Oct 2005 A1
20050261642 Weston Nov 2005 A1
20050261643 Bybordi et al. Nov 2005 A1
20060015087 Risk, Jr. et al. Jan 2006 A1
20060025727 Boehringer et al. Feb 2006 A1
20060029650 Coffey Feb 2006 A1
20060039742 Cable, Jr. et al. Feb 2006 A1
20060041247 Petrosenko et al. Feb 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060100594 Adams et al. May 2006 A1
20060116620 Oyaski Jun 2006 A1
20060149170 Boynton et al. Jul 2006 A1
20070005028 Risk, Jr. et al. Jan 2007 A1
20070014837 Johnson et al. Jan 2007 A1
20070016152 Karpowicz Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffmann et al. Feb 2007 A1
20070032754 Walsh Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070066946 Haggstrom et al. Mar 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20070167927 Hunt et al. Jul 2007 A1
20070179460 Adahan Aug 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070233022 Henley et al. Oct 2007 A1
20080071235 Locke et al. Mar 2008 A1
20080200857 Lawhorn Aug 2008 A1
20080200906 Sanders et al. Aug 2008 A1
20080208147 Argenta et al. Aug 2008 A1
20080234641 Locke et al. Sep 2008 A1
Foreign Referenced Citations (40)
Number Date Country
41 11 122 Apr 1993 DE
295 04 378 Oct 1995 DE
0 020 662 Jul 1984 EP
0 358 302 Mar 1990 EP
1088589 Apr 2001 EP
1219311 Jul 2002 EP
0 853 950 Oct 2002 EP
1 549 756 Mar 1977 GB
2 195 255 Apr 1988 GB
2 235 877 Mar 1991 GB
2307180 May 1997 GB
2329127 Mar 1999 GB
2336546 Oct 1999 GB
2344531 Jun 2000 GB
2 415 908 Jan 2006 GB
1762940 Jan 1989 SU
8001139 Jun 1980 WO
8002182 Oct 1980 WO
8401904 May 1984 WO
8905133 Jun 1989 WO
9011795 Oct 1990 WO
9219313 Nov 1992 WO
9309727 May 1993 WO
9420041 Sep 1994 WO
9605873 Feb 1996 WO
9605873 Feb 1996 WO
0021586 Apr 2000 WO
03005943 Jan 2003 WO
03018098 Mar 2003 WO
03030966 Apr 2003 WO
03057070 Jul 2003 WO
03057307 Jul 2003 WO
03057307 Jul 2003 WO
03045492 Aug 2003 WO
03086232 Oct 2003 WO
03092620 Nov 2003 WO
03101508 Dec 2003 WO
2004018020 Mar 2004 WO
2005009488 Feb 2005 WO
2006105892 Oct 2006 WO
Related Publications (1)
Number Date Country
20090326487 A1 Dec 2009 US
Provisional Applications (1)
Number Date Country
61076753 Jun 2008 US